Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and kliogest® for continuous combined hormone replacement therapy in postmenopausal women

Climacteric

Volumn 3, Issue 2, 2000, Pages 109-118

  Graser T ^a   Koytchev, R ^b   Muller A ^a   Oettel, M ^a  

^a BAYER PHARMA AG   (Germany)

^b Coop Clin Drug Res/Development ^*  (Germany)

Author keywords

Climodien; Continuous combined hrt; Dienogest; Endometrium; Estradiol valerate; Hormone replacement therapy; Kliogest

Indexed keywords

DIENOGEST; DIENOGEST PLUS ESTRADIOL VALERATE; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRADIOL VALERATE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN;

ADULT; ARTICLE; BREAST DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSMENORRHEA; ENDOMETRIUM ATROPHY; ENDOMETRIUM BIOPSY; FEMALE; GASTROINTESTINAL SYMPTOM; HORMONE SUBSTITUTION; HUMAN; LUNG TOXICITY; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROTOXICITY; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; VAGINA BLEEDING;

EID: 0033854572     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.3109/13697130009167612     Document Type: Article

References (30)

1. 1. Tang MS, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age of onset of Alzheimer's disease. Lancet 1996;348:429-32
2. 2. Gambrell RD Jr. Prevention of endometrial cancer with progestogens. Maturitas 1988;8: 159-68
3. 3. Hammond CB, Jelovsek FR, Lee KL, Creasman WT, Parker RT. Effects of long-term estrogen replacement therapy. II Neoplasia. Am J Obstet Gynecol 1979;133:537-47
4. 4. Persson I, Adami H-O, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. Br Med J 1989; 298:147-51
5. 5. Whitehead MI, Townsend PT, Pryse-Davies J, Ryder TA, King RJB. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 1981;305:1599-605
6. 6. Whitehead MI, Fraser D. The effects of estrogens and progestogens on the endometrium: a modern approach to treatment. Obstet Gynecol Clin North Am 1987;14:299-319
7. 7. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 1988;159:312-17
8. 8. Bolaji II, Grimes H, Mortimer G, Talion DF, Fottrel PF, Eamon MO. Low-dose progesterone therapy in oestrogenised postmenopausal women: effects of plasma lipids, lipoproteins and liver function parameters. Eur J Obstet Gynecol 1993;48:61-8
9. 9. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998;280: 605-13
10. 10. Mattsson L-Å, Cullberg G, Samsioe G. Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints. Maturitas 1982;4:95-102
11. 11. Obel EB, Munk-Jensen N, Svenstrup B, et al. A two-year double-blind controlled study of the clinical effect of combined and sequential post-menopausal replacement therapy and steroid metabolism during treatment. Maturitas 1993; 16:13-21
12. 12. Staland B. Continuous treatment with natural oestrogens and progestogens. A method to avoid endometrial stimulation. Maturitas 1981;3: 145-56
13. 13. Christiansen C, Riis BJ. Five years with continuous combined oestrogen/progestogen therapy. Effects of calcium metabolism, lipoproteins, and bleeding pattern. Br J Obstet Gynaecol 1990;97: 1087-92
14. 14. Hassager C, Christiansen C. Blood pressure during oestrogen/progestogen substitution therapy in healthy post-menopausal women. Maturitas 1988;9:315-23
15. 15. Campagnoli C, Biglia N, Lanza MG, Lesca L, Peris C, Sismondi P. Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated estrogens in postmenopausal women. Preliminary report. Maturitas 1994;19:25-31
16. 16. Cullen KJ, Allison A, Martire I, Ellis M, Singer C. Insulin-like growth factor expression in breast cancer epithelium and stroma. Breast Cancer Res Treat 1992;22:21-9
17. 17. Jordan VC, Fritz NF, Tormey DC. Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. Cancer Res 1987;47:4517-19
18. 18. Staffa JA, Newschaffer CJ, Jones JK, Miller V. Progestins and breast cancer: an epidemiologic review. Fertil Steril 1992;57:473-91
19. 19. Byrjalsen I, Thormann L, Meinecke B, Riis BJ, Christiansen C. Serum placental protein 14 (PP14) reflects endometrial status during hormone replacement therapy. Hum Reprod 1992;7:1042-7
20. 20. Stanczyk FZ. Introduction: structure-function relationships, metabolism, pharmacokinetics and potency of progestins. Drugs Today 1996;32 (Suppl H):1-14
21. 21. Müller A, Mück AO, Gräser T, Mellinger U, Oettel M, Lippert TH. The influence of a continuous-combined HRT regimen with estradiol valerate and dienogest on bleeding pattern and endometrium of postmenopausal women. J Menopause 1998;5:17-22
22. 22. Gräser T, Oettel M. Organ targeting with the oral progestin dienogest. Drugs Today 1996;32 (Suppl H):43-55
23. 23. Oettel M, Carol W, Elger W, et al. A 19-norprogestin without a 17α-ethinyl group. II. Dienogest from a pharmacodynamic point of view. Drugs Today 1995;31:517-36
24. 24. Katsuki Y, Shibutani Y, Aoki D, Nozawa S. Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins. Cancer 1997;79:169-76
25. 25. Udoff L, Langenberg P, Adashi EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 1995;86:306-16
26. 26. Kupperman HS, Blatt MHG, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol 1953;13: 688-703
27. 27. Marslew U, Riis B, Christiansen C. Progestogens: therapeutic and adverse effects in early post-menopausal women. Maturitas 1991;13:7-16
28. 28. Committee for Proprietary Medicinal Products. Points to Consider on Hormone Replacement Therapy. CPMP/EWP/021/97. London: CPMP, 1997
29. 29. Whitehead MI, Hillard TC, Crook D. The role and use of progestogens. Obstet Gynecol 1990; 75:59S-76S
30. 30. Kuhnz W, Heuner A, Hümpel M, Seifert W, Michaelis K. In vivo conversion of norethisterone and norethisterone acetate to ethinyl estradiol in postmenopausal women. Contraception 1997; 56:379-85